TY - JOUR
T1 - Biomarkers for advancing diagnosis and prognosis in stroke
AU - BIOSTROKE investigators
AU - Tiedt, Steffen
AU - Bustamante, Alejandro
AU - Cameron, Alan
AU - Camps-Renom, Pol
AU - Grosse, Gerrit M.
AU - Ospel, Johanna
AU - Volbers, Bastian
AU - Audebert, Heinrich J.
AU - Aulin, Julia
AU - Cheng, Bastian
AU - Cordonnier, Charlotte
AU - Coutinho, Jonathan M.
AU - Fonseca, Ana Catarina
AU - Hill, Michael D.
AU - Jensen, Märit
AU - Jern, Christina
AU - Kamtchum-Tatuene, Joseph
AU - Katan, Mira
AU - Kelly, Peter J.
AU - Kopczak, Anna
AU - Lemmens, Robin
AU - Lindgren, Arne G.
AU - Loan, James J.M.
AU - Nolte, Christian H.
AU - Puy, Laurent
AU - Saba, Luca
AU - Salman, Rustam Al Shahi
AU - Sandset, Else Charlotte
AU - Selim, Magdy H.
AU - Seners, Pierre
AU - Sprigg, Nikola
AU - Tsai, Hsin Hsi
AU - Doyle, Karen M.
AU - Montaner, Joan
AU - Schreuder, Floris H.B.M.
AU - Sposato, Luciano
AU - Samarasekera, Neshika
AU - McCabe, John J.
AU - Parry-Jones, Adrian R.
AU - Lambea, Alvaro
AU - Morotti, Andrea
AU - Balabanski, Anna H.
AU - Ramos-Pachon, Anna
AU - Zietz, Annaelle
AU - Aamodt, Anne Hege
AU - Katsanos, Aristeidis H.
AU - Abdul-Rahim, Azmil H.
AU - Roussel, Benoit D.
AU - Freedman, Ben
AU - Tan, Benjamin Y.Q.
N1 - Publisher Copyright:
© 2025 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license. http://creativecommons.org/licenses/by/4.0/
PY - 2026/4
Y1 - 2026/4
N2 - Summary The complexity and incomplete understanding of the pathophysiology of stroke poses substantial challenges to personalised medicine and the development of novel therapies, as reflected in the neutral results of many randomised trials. Current clinical algorithms lack the precision to diagnose stroke before hospital admission, predict disease progression and recovery, or assess recurrence risk. Biomarkers are urgently needed, yet the absence of a robust evidence base hinders their clinical translation. To lay the groundwork for addressing this knowledge gap, an international multidisciplinary panel of stroke experts conducted a literature review that informed a Delphi consensus process. The stroke experts panel proposes 17 research priorities and five minimum reporting datasets for stroke biomarker studies, each corresponding to a key domain of stroke care: prehospital diagnosis, ischaemic stroke progression, atrial cardiopathy, plaque vulnerability, and intracerebral haemorrhage. This framework will promote consistency and collaboration towards the discovery, validation, and clinical translation of biomarkers to improve stroke care.
AB - Summary The complexity and incomplete understanding of the pathophysiology of stroke poses substantial challenges to personalised medicine and the development of novel therapies, as reflected in the neutral results of many randomised trials. Current clinical algorithms lack the precision to diagnose stroke before hospital admission, predict disease progression and recovery, or assess recurrence risk. Biomarkers are urgently needed, yet the absence of a robust evidence base hinders their clinical translation. To lay the groundwork for addressing this knowledge gap, an international multidisciplinary panel of stroke experts conducted a literature review that informed a Delphi consensus process. The stroke experts panel proposes 17 research priorities and five minimum reporting datasets for stroke biomarker studies, each corresponding to a key domain of stroke care: prehospital diagnosis, ischaemic stroke progression, atrial cardiopathy, plaque vulnerability, and intracerebral haemorrhage. This framework will promote consistency and collaboration towards the discovery, validation, and clinical translation of biomarkers to improve stroke care.
UR - https://www.scopus.com/pages/publications/105034086888
U2 - 10.1016/S1474-4422(25)00480-6
DO - 10.1016/S1474-4422(25)00480-6
M3 - Artículo de revisión
C2 - 41864237
AN - SCOPUS:105034086888
SN - 1474-4422
VL - 25
SP - 406
EP - 420
JO - The Lancet Neurology
JF - The Lancet Neurology
IS - 4
ER -